Raymond James Financial Services Advisors Inc. raised its stake in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 183.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,077 shares of the company's stock after buying an additional 84,813 shares during the quarter. Raymond James Financial Services Advisors Inc. owned about 0.50% of Abrdn Life Sciences Investors worth $1,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of HQL. Cambridge Investment Research Advisors Inc. increased its stake in Abrdn Life Sciences Investors by 15.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 14,930 shares of the company's stock worth $247,000 after acquiring an additional 1,982 shares during the last quarter. NewEdge Advisors LLC increased its position in Abrdn Life Sciences Investors by 65.1% in the first quarter. NewEdge Advisors LLC now owns 24,099 shares of the company's stock worth $398,000 after purchasing an additional 9,500 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in Abrdn Life Sciences Investors in the first quarter worth $662,000. IHT Wealth Management LLC purchased a new stake in Abrdn Life Sciences Investors during the first quarter valued at $170,000. Finally, Eudaimonia Partners LLC bought a new position in Abrdn Life Sciences Investors during the first quarter valued at $199,000. Institutional investors own 32.21% of the company's stock.
Abrdn Life Sciences Investors Price Performance
Shares of NYSE:HQL remained flat at $13.19 on Thursday. 30,223 shares of the company's stock were exchanged, compared to its average volume of 112,129. The business has a 50-day moving average price of $13.69 and a 200-day moving average price of $13.06. Abrdn Life Sciences Investors has a 1-year low of $11.34 and a 1-year high of $14.37.
Abrdn Life Sciences Investors Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, February 22nd were given a $0.39 dividend. The ex-dividend date of this dividend was Wednesday, February 21st. This represents a $1.56 annualized dividend and a yield of 11.83%. This is a positive change from Abrdn Life Sciences Investors's previous quarterly dividend of $0.30.
Abrdn Life Sciences Investors Company Profile
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Further Reading
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
